24/7 Market News Snapshot 15 April, 2025 – Skye Bioscience, Inc. Common Stock (NASDAQ:SKYE)

April 15, 2025

DENVER, Colo., 15 April, 2025 (www.247marketnews.com) – (NASDAQ:SKYE) are discussed in this article.
Skye Bioscience, Inc. has showcased extraordinary market performance today, opening at $1.48 and soaring to a remarkable $2.88, representing an impressive increase of 119.85%. The company’s stock had a previous close of $1.31, and with a trading volume of 505,000 shares, investor enthusiasm has been significantly heightened. This surge in stock value signals heightened investor interest, spurring market analysts to closely monitor potential breakout levels and further developments.

The excitement surrounding Skye is further fueled by its groundbreaking advancements in metabolic health, particularly through the preclinical findings related to nimacimab, a novel CB1 antibody targeting obesity. Recent data from a murine diet-induced obesity model revealed that nimacimab achieved a substantial 23.5% weight loss during a 25-day treatment period when administered alone. Additionally, when combined with tirzepatide, a dual GLP-1/GIP agonist, weight loss surpassed 30%. These results underscore nimacimab’s dual efficacy as both a standalone and complementary therapy for obesity.

Skye’s CEO, Punit Dhillon, highlighted the significance of nimacimab’s therapeutic approach, specifically its capacity to promote considerable weight loss while minimizing the neuropsychiatric side effects commonly seen with traditional CB1 inhibitors. The company reported nimacimab’s unique allosteric binding mechanism, demonstrating superior potency compared to traditional small molecule competitors like monlunabant, which faces challenges in competitive environments.

Looking ahead, Skye anticipates releasing top-line results from its Phase 2a CBeyond™ clinical trial in late Q3 to early Q4 of 2025. This data is expected to solidify confidence in nimacimab’s potential both as an independent treatment and in conjunction with GLP-1-targeted therapies. Skye Bioscience is dedicated to reshaping obesity management, standing at the forefront of an evolving healthcare landscape.

Related news for (SKYE)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.